(Q36464907)

14 August 2017

1 reference

title

Gene transfer approaches for gynecological diseases (English)

1 reference

14 August 2017

4

Akseli Hemminki

1 reference

14 August 2017

3

Anna Kanerva

1 reference

14 August 2017

Mari Raki

1

1 reference

14 August 2017

Daniel T Rein

series ordinal

2

1 reference

14 August 2017

publication date

2 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

14

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

154-163

1 reference

Global cancer statistics, 2002

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Adenoviruses for treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Targeted gene therapy of ovarian cancer using an ovarian-specific promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Adenovirus-based p53 gene therapy in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Why did p53 gene therapy fail in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Targeted tumor killing via an intracellular antibody against erbB-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Adenoviral-mediated suicide gene therapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

New developments in the virus therapy of cancer: a historical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Replicative adenoviruses for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Tissue-specific promoters for cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

A DNA recombination-based approach to eliminate papillomavirus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Circulating angiogenic factors and the risk of preeclampsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Gene transfer to the rodent placenta in situ. A new strategy for delivering gene products to the fetus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Angiographically guided utero-placental gene transfer in rabbits with adenoviruses, plasmid/liposomes and plasmid/polyethyleneimine complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Adenovirally Mediated Expression of Insulin-Like Growth Factors Enhances the Function of First Trimester Placental Fibroblasts

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

inferred from DOI database lookup

7 January 2021

based on heuristic

The role of HOX genes in human implantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Alteration of maternal Hoxa10 expression by in vivo gene transfection affects implantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Fluorescently labeled adenovirus with pIX-EGFP for vector detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Modified adenoviruses for cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Gene transfer as a tool to induce therapeutic vascular growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Gene transfer to cervical cancer with fiber-modified adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2006.02.019

1 reference

14 August 2017

1 reference